Revolution Medicines (RVMD) CDO details initial option and RSU stake

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Development Officer Alan B. Sandler filed an initial beneficial ownership report. He directly holds 53,000 shares of Common Stock, which include 53,000 Restricted Stock Units. He also holds stock options over 167,300 shares at an exercise price of $58.84 per share expiring on October 31, 2035, and options over 11,700 shares at $102.02 per share expiring on February 28, 2036. These options vest monthly over four years starting from vesting commencement dates on November 1, 2025 and March 1, 2026, subject to his continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Sandler Alan B.

Role Chief Development Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 167,300 shares (Direct); Common Stock — 53,000 shares (Direct)

Footnotes (1)

1. Includes 53,000 Restricted Stock Units. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from November 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sandler Alan B.

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/20/2026

3. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	53,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	10/31/2035	Common Stock	167,300	$58.84	D
Stock Option (Right to Buy)	(3)	02/28/2036	Common Stock	11,700	$102.02	D

Explanation of Responses:

1. Includes 53,000 Restricted Stock Units.

2. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from November 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jack Anders, as Attorney-in-fact for Alan Sandler	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did RVMD Chief Development Officer Alan Sandler report on his Form 3?

Alan Sandler reported his initial beneficial ownership in Revolution Medicines. He holds 53,000 Common Stock shares including Restricted Stock Units and stock options over additional shares that vest over time, subject to his continued service with the company.

How many Revolution Medicines (RVMD) shares does Alan Sandler currently hold?

Alan Sandler directly holds 53,000 shares of Revolution Medicines Common Stock. A footnote clarifies these 53,000 shares are Restricted Stock Units, which typically settle in stock as they vest, aligning his compensation with shareholder value over time.

What stock options does Alan Sandler have in Revolution Medicines (RVMD)?

Alan Sandler holds options over 167,300 RVMD shares at an exercise price of $58.84 expiring October 31, 2035. He also holds options over 11,700 shares at $102.02 expiring February 28, 2036, providing potential future ownership if exercised.

How do Alan Sandler’s RVMD stock options vest over time?

One option grant vests 25% on November 1, 2026, then monthly so it is fully vested by the fourth anniversary of November 1, 2025. The other grant vests monthly from March 1, 2026, also completing on its fourth anniversary, contingent on continued service.

What is the significance of Alan Sandler’s Form 3 for RVMD investors?

The Form 3 shows Alan Sandler’s initial equity stake as Chief Development Officer. It details his Restricted Stock Units and option grants, illustrating long-term, service-based incentives that link a key executive’s potential rewards to Revolution Medicines’ share performance.